Prestige Consumer Healthcare (NYSE:PBH – Get Rating) and Gemini Therapeutics (NASDAQ:GMTX – Get Rating) are both consumer discretionary companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.
This table compares Prestige Consumer Healthcare and Gemini Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Prestige Consumer Healthcare||18.53%||13.27%||5.55%|
Insider and Institutional Ownership
99.4% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 83.4% of Gemini Therapeutics shares are held by institutional investors. 1.6% of Prestige Consumer Healthcare shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Prestige Consumer Healthcare||$1.09 billion||2.32||$205.38 million||$3.99||12.72|
|Gemini Therapeutics||N/A||N/A||-$71.87 million||($1.35)||-1.01|
Prestige Consumer Healthcare has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and price targets for Prestige Consumer Healthcare and Gemini Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Prestige Consumer Healthcare||0||2||2||0||2.50|
Prestige Consumer Healthcare currently has a consensus target price of $80.50, indicating a potential upside of 58.62%. Gemini Therapeutics has a consensus target price of $6.90, indicating a potential upside of 403.65%. Given Gemini Therapeutics’ higher probable upside, analysts clearly believe Gemini Therapeutics is more favorable than Prestige Consumer Healthcare.
Risk & Volatility
Prestige Consumer Healthcare has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.16, indicating that its share price is 116% less volatile than the S&P 500.
Prestige Consumer Healthcare beats Gemini Therapeutics on 10 of the 12 factors compared between the two stocks.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
About Gemini Therapeutics
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.